• LAST PRICE
    1.9700
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-1.0050%)
  • Bid / Lots
    1.9700/ 1
  • Ask / Lots
    2.0000/ 1
  • Open / Previous Close
    2.0300 / 1.9900
  • Day Range
    Low 1.9301
    High 2.0300
  • 52 Week Range
    Low 1.9000
    High 65.8500
  • Volume
    7,044
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.99
TimeVolumeMYMD
09:32 ET4332
09:56 ET4001.9999
09:57 ET1001.9657
10:19 ET4851.9301
10:30 ET10001.965
10:35 ET1061.9999
10:39 ET5002
10:55 ET1251.9999
11:13 ET1001.9776
11:31 ET1001.97
12:34 ET2002
01:39 ET21361.9701
02:02 ET1001.97
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMYMD
Mymd Pharmaceuticals Inc
4.6M
-0.4x
---
United StatesCEOS
CeCors Inc
4.6M
0.0x
---
United StatesGBLX
GB Sciences Inc
4.6M
-0.8x
---
United StatesARTL
Artelo Biosciences Inc
4.5M
-0.4x
---
United StatesABTI
Alterola Biotech Inc
4.5M
-7.5x
---
United StatesGOVX
GeoVax Labs Inc
4.4M
-0.1x
---
As of 2024-05-30

Company Information

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Contact Information

Headquarters
855 N. Wolfe Street, Suite 601BALTIMORE, MD, United States 21205
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Joshua Silverman
President, Director, Chief Medical Officer
Chris Chapman
Interim Chief Financial Officer
Ian Rhodes
Executive Vice President - Operations, General Counsel, Chief Legal Officer
Paul Rivard
Chief Scientific Officer
Adam Kaplin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.6M
Revenue (TTM)
$0.00
Shares Outstanding
2.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.07
EPS
$-5.53
Book Value
$11.17
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.